FBLG

FibroBiologics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website fibrobiologics.com
Employees(FY) 8
ISIN US31573L1052

Performance

+2.5%

-26.79%

-44.41%

-68.22%

-18.0%

YTD

-94.36%

Profile

FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for treating wound healing. Its early-stage research programs include CYTER915 which is designed to regenerate or reinvigorate production of the thymus and/or spleen; and TCB190 for the treatment of cancers. The company was incorporated in 2021 and is based in Houston, Texas. FibroBiologics, Inc. operates as a subsidiary of Spinalcyte Llc.

Advanced Technical Analysis

Technical Analysis of FBLG 2025-01-31

The stock indicators reflect a bearish sentiment, with a Moving Average Score of 10, an Oscillators Score of 43, and a Technical Score of 15, indicating overall weakness in momentum and trend direction. The low scores suggest that caution is warranted for potential investors, as the market appears to be under pressure.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of FBLG

Stock Rank

Recent News & Updates

2024-12-30 03:30
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing(Globenewswire)
2024-12-30 01:12
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing(Globenewswire)
2024-12-22 18:55
FibroBiologics Announces $25 Million Financing(Globenewswire)
2024-11-18 20:15
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly(Globenewswire)
2024-11-13 20:15
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics(Globenewswire)
2024-11-12 03:20
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-10-28 21:15
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology(Globenewswire)
2024-10-27 21:31
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024(Globenewswire)
2024-10-20 19:45
FibroBiologics and Charles River link for chronic disease therapies manufacture(Yahoo Finance)
2024-10-17 20:30
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases(Globenewswire)
2024-10-15 21:15
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office(Globenewswire)
2024-10-10 21:31
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit(Globenewswire)
2024-09-29 21:31
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa(Globenewswire)
2024-09-18 21:31
FibroBiologics Engages Southern Star Research as CRO in Australia(Globenewswire)
2024-09-11 21:31
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology(Globenewswire)
2024-09-05 21:31
FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-19 21:31
FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology(Globenewswire)
2024-08-07 06:52
FibroBiologics Files 2024 Second Quarter Report(Globenewswire)
2024-07-14 21:31
FibroBiologics to Present at JonesTrading Healthcare Summit 2024(Globenewswire)
2024-06-24 21:31
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology(Globenewswire)
2024-06-12 21:31
FibroBiologics Set to Join Russell 2000 Index(Globenewswire)
2024-06-05 21:31
FibroBiologics to Present at Extracellular Matrix Pharmacology Congress 2024(Globenewswire)
2024-05-15 04:30
FibroBiologics Announces 2024 Annual Meeting of Stockholders(Globenewswire)
2024-05-14 21:54
FBLG Stock Earnings: FibroBiologics, Inc. - Common Stock Reported Results for Q1 2024(Investorplace)
2024-05-14 05:24
FibroBiologics Files 2024 First Quarter Report(Globenewswire)
2024-05-06 21:31
FibroBiologics to Present at the BIO International Convention 2024(Globenewswire)
2024-04-24 20:00
FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids(Globenewswire)
2024-04-10 21:31
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office(Globenewswire)
2024-04-03 21:31
FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA(Globenewswire)
2024-03-27 21:31
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus(Globenewswire)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.